Market Research Logo

Thrombosis - Pipeline Review, H2 2015

Thrombosis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Thrombosis - Pipeline Review, H2 2015’, provides an overview of the Thrombosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Thrombosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Thrombosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Thrombosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Thrombosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Thrombosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Thrombosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Thrombosis Overview
Therapeutics Development
Pipeline Products for Thrombosis - Overview
Pipeline Products for Thrombosis - Comparative Analysis
Thrombosis - Therapeutics under Development by Companies
Thrombosis - Therapeutics under Investigation by Universities/Institutes
Thrombosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Thrombosis - Products under Development by Companies
Thrombosis - Products under Investigation by Universities/Institutes
Thrombosis - Companies Involved in Therapeutics Development
3SBio Inc.
Antibe Therapeutics, Inc.
Archemix Corp.
Arena Pharmaceuticals, Inc.
Armetheon, Inc.
Arrowhead Research Corporation
Astellas Pharma Inc.
AstraZeneca Plc
Bayer AG
Bristol-Myers Squibb Company
Cardax Pharmaceuticals, Inc.
Cereno Scientific AB
China Biologic Products, Inc.
CSL Limited
Daewoong Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
Dyax Corp.
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
Gamma Therapeutics, Inc.
Generex Biotechnology Corporation
GlycoMimetics, Inc.
Green Cross Corporation
IMMD Inc.
Isis Pharmaceuticals, Inc.
Johnson & Johnson
Laboratorios Farmaceuticos Rovi, S.A.
LG Life Science LTD.
Lipicard Technologies Limited
Merrion Pharmaceuticals Plc
Nihon Pharmaceutical Industry Co., Ltd.
Nostrum Pharmaceuticals, LLC
Pfizer Inc.
PLx Pharma Inc.
Portola Pharmaceuticals, Inc.
Prothix BV
Sagene Pharmaceuticals, Inc.
Sanofi
SciFluor Life Sciences, LLC
The International Biotechnology Center (IBC) Generium
Zedira GmbH
Zydus Cadila Healthcare Limited
Thrombosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AB-012 - Drug Profile
alteplase biosimilar - Drug Profile
Antisense RNAi Oligonucleotide for DVT - Drug Profile
antithrombin III (human) - Drug Profile
ANV-6L15 - Drug Profile
apixaban - Drug Profile
ARC-15105 - Drug Profile
ARCF-12 - Drug Profile
AS-1468240 - Drug Profile
ASP-1645 - Drug Profile
ASP-6537 - Drug Profile
aspirin - Drug Profile
ATB-340 - Drug Profile
BAY-1213790 - Drug Profile
betrixaban - Drug Profile
Biosimilar 4 for Acute Myocardial Infarction, Infertility and Thrombosis - Drug Profile
BMS-262084 - Drug Profile
BMS-593214 - Drug Profile
BMS-654457 - Drug Profile
BMS-816106 - Drug Profile
BMS-884775 - Drug Profile
BMS-986120 - Drug Profile
BMS-986141 - Drug Profile
BMS-986177 - Drug Profile
C-3 - Drug Profile
CDX-085 - Drug Profile
CSL-312 - Drug Profile
DD-2 - Drug Profile
Drug to Activate Endothelial Protein C Receptor for Inflammation and Thrombosis - Drug Profile
Drugs for Thrombosis - Drug Profile
DS-9231 - Drug Profile
DWJ-1261 - Drug Profile
DWJ-1355 - Drug Profile
DX-4012 - Drug Profile
E-5539 - Drug Profile
edoxaban tosylate - Drug Profile
enoxaparin biosimilar - Drug Profile
ER-410660 - Drug Profile
fondaparinux sodium - Drug Profile
fondaparinux sodium - Drug Profile
Gammarin - Drug Profile
GCC-2107 - Drug Profile
GMI-1271 - Drug Profile
IMD-4852 - Drug Profile
ISIS-FVIIRx - Drug Profile
ISIS-FXIRx - Drug Profile
JNJ-375 - Drug Profile
LC-231306 - Drug Profile
LT-5121 - Drug Profile
LT-5122 - Drug Profile
LT–5521 - Drug Profile
Lysimab - Drug Profile
Monoclonal Antibody to Inhibit TAFI and PAI-1 for Thrombosis and Stroke - Drug Profile
nadroparin calcium - Drug Profile
NPB-06 - Drug Profile
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile
Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
PF-00190434 - Drug Profile
Polysaccharide to Inhibit Factor X for Deep Vein Thrombosis - Drug Profile
PRO-01 - Drug Profile
Protein for Thromboembolism - Drug Profile
PRT-060318 - Drug Profile
PZ-128 - Drug Profile
Recombinant Protein for Thrombosis and Non-Small Cell Lung Cancer - Drug Profile
Recombinant Protein for Thrombosis and Stroke - Drug Profile
Recombinant Protein Slit2 to Agonize Robo1 for Ischemia Reperfusion Injury and Thrombosis - Drug Profile
Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis - Drug Profile
rGPG-290 - Drug Profile
rivaroxaban - Drug Profile
S-002333 - Drug Profile
S-007867 - Drug Profile
SAR-216471 - Drug Profile
selegiline + Antiplatelet Drugs - Drug Profile
semuloparin sodium - Drug Profile
Small Molecule 2 to Inhibit Factor XIa for Thrombosis - Drug Profile
Small Molecule for Thrombosis - Drug Profile
Small Molecule for Thrombosis - Drug Profile
Small Molecule to Antagonize P2Y12 for Thrombosis - Drug Profile
Small Molecule to Antagonize PAR4 for Thromboembolic Disorders - Drug Profile
Small Molecule to Inhibit ASK1 for Thrombosis - Drug Profile
Small Molecule To Inhibit Factor Xa for Thrombosis - Drug Profile
Small Molecule to Inhibit PAR-1 for Atherothrombosis - Drug Profile
Small Molecules for Hematological Disorders and Cancer - Drug Profile
Small Molecules for Thrombosis - Drug Profile
Small Molecules to Inhibit Carboxypeptidase U for Thrombosis - Drug Profile
Small Molecules to Inhibit Factor XIa for Stroke and Thrombosis - Drug Profile
Small Molecules to Inhibit Factor XIII for Thrombosis - Drug Profile
Small Molecules to Inhibit HDAC for Thromboembolism - Drug Profile
Small Molecules to Inhibit P2Y12 Receptor for Thrombosis - Drug Profile
Small Molecules to Inhibit PDI for Thrombosis - Drug Profile
SMRX-11 - Drug Profile
Synthetic Peptide to Inhibit Factor II for Thrombosis, Restenosis and Brain Injury - Drug Profile
Synthetic Peptides to Inhibit Glycoprotein VI for Thrombosis - Drug Profile
TAP-ANV - Drug Profile
tecarfarin sodium - Drug Profile
temanogrel hydrochloride - Drug Profile
ticagrelor - Drug Profile
TM-5275 - Drug Profile
TM-5509 - Drug Profile
TRX-1 - Drug Profile
TTS-01 - Drug Profile
UM-8190 - Drug Profile
YG-001 - Drug Profile
Thrombosis - Recent Pipeline Updates
Thrombosis - Dormant Projects
Thrombosis - Discontinued Products
Thrombosis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Thrombosis, H2 2015
Number of Products under Development for Thrombosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Thrombosis - Pipeline by 3SBio Inc., H2 2015
Thrombosis - Pipeline by Antibe Therapeutics, Inc., H2 2015
Thrombosis - Pipeline by Archemix Corp., H2 2015
Thrombosis - Pipeline by Arena Pharmaceuticals, Inc., H2 2015
Thrombosis - Pipeline by Armetheon, Inc., H2 2015
Thrombosis - Pipeline by Arrowhead Research Corporation, H2 2015
Thrombosis - Pipeline by Astellas Pharma Inc., H2 2015
Thrombosis - Pipeline by AstraZeneca Plc, H2 2015
Thrombosis - Pipeline by Bayer AG, H2 2015
Thrombosis - Pipeline by Bristol-Myers Squibb Company, H2 2015
Thrombosis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2015
Thrombosis - Pipeline by Cereno Scientific AB, H2 2015
Thrombosis - Pipeline by China Biologic Products, Inc., H2 2015
Thrombosis - Pipeline by CSL Limited, H2 2015
Thrombosis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015
Thrombosis - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Thrombosis - Pipeline by Dyax Corp., H2 2015
Thrombosis - Pipeline by Eisai Co., Ltd., H2 2015
Thrombosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Thrombosis - Pipeline by Gamma Therapeutics, Inc., H2 2015
Thrombosis - Pipeline by Generex Biotechnology Corporation, H2 2015
Thrombosis - Pipeline by GlycoMimetics, Inc., H2 2015
Thrombosis - Pipeline by Green Cross Corporation, H2 2015
Thrombosis - Pipeline by IMMD Inc., H2 2015
Thrombosis - Pipeline by Isis Pharmaceuticals, Inc., H2 2015
Thrombosis - Pipeline by Johnson & Johnson, H2 2015
Thrombosis - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H2 2015
Thrombosis - Pipeline by LG Life Science LTD., H2 2015
Thrombosis - Pipeline by Lipicard Technologies Limited, H2 2015
Thrombosis - Pipeline by Merrion Pharmaceuticals Plc, H2 2015
Thrombosis - Pipeline by Nihon Pharmaceutical Industry Co., Ltd., H2 2015
Thrombosis - Pipeline by Nostrum Pharmaceuticals, LLC, H2 2015
Thrombosis - Pipeline by Pfizer Inc., H2 2015
Thrombosis - Pipeline by PLx Pharma Inc., H2 2015
Thrombosis - Pipeline by Portola Pharmaceuticals, Inc., H2 2015
Thrombosis - Pipeline by Prothix BV, H2 2015
Thrombosis - Pipeline by Sagene Pharmaceuticals, Inc., H2 2015
Thrombosis - Pipeline by Sanofi, H2 2015
Thrombosis - Pipeline by SciFluor Life Sciences, LLC, H2 2015
Thrombosis - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2015
Thrombosis - Pipeline by Zedira GmbH, H2 2015
Thrombosis - Pipeline by Zydus Cadila Healthcare Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Thrombosis Therapeutics - Recent Pipeline Updates, H2 2015
Thrombosis - Dormant Projects, H2 2015
Thrombosis - Dormant Projects (Contd..1), H2 2015
Thrombosis - Dormant Projects (Contd..2), H2 2015
Thrombosis - Dormant Projects (Contd..3), H2 2015
Thrombosis - Dormant Projects (Contd..4), H2 2015
Thrombosis - Dormant Projects (Contd..5), H2 2015
Thrombosis - Dormant Projects (Contd..6), H2 2015
Thrombosis - Dormant Projects (Contd..7), H2 2015
Thrombosis - Dormant Projects (Contd..8), H2 2015
Thrombosis - Dormant Projects (Contd..9), H2 2015
Thrombosis - Discontinued Products, H2 2015
Thrombosis - Discontinued Products (Contd..1), H2 2015
Thrombosis - Discontinued Products (Contd..2), H2 2015
Thrombosis - Discontinued Products (Contd..3), H2 2015
List of Figures
Number of Products under Development for Thrombosis, H2 2015
Number of Products under Development for Thrombosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report